TuHURA Biosciences (HURA) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Organigram Global (OGI) over the past year, losing 24.0% versus a loss of 51.0%. Over five years, OGI leads with a -89.4% price change compared with -99.9% for HURA. Organigram Global is the larger company by market cap ($138.3 million vs $124.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HURA | OGI |
|---|---|---|
| Share price | $1.96 | $0.9593 |
| Market cap | $124.90M | $138.29M |
| 1-day change | +1.55% | +0.86% |
| YTD return | +158.92% | -43.39% |
| 1-year return | -24.03% | -50.97% |
| 5-year return | -99.87% | -89.39% |
| P/E ratio (TTM) | — | 2.18 |
| Forward P/E | — | 39.97 |
| EPS (TTM) | $-0.54 | $0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.43 | $2.24 |
| 52-week low | $0.41 | $0.853 |
| Distance from 52-week high | -42.86% | -57.17% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +310.20% | — |
| Average volume | 250.11K | 884.72K |
| Shares outstanding | 63.73M | 144.15M |
| Employees | 22 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed OGI by 26.9 percentage points over the past year.
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
HURA vs OGI FAQ
Which is bigger, TuHURA Biosciences or Organigram Global?
Organigram Global (OGI) is larger, with a market capitalization of $138.29M compared with $124.90M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, HURA or OGI?
HURA returned -24.03% over the past 12 months, compared with -50.97% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are TuHURA Biosciences and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.